News
Biogen submits MAA at EMA for aducanumab, an investigational treatment for Alzheimer’s disease.
Eisai Co., Ltd. announced that Biogen has disclosed its submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the review of aducanumab, an investigational treatment for Alzheimer’s disease, as of October 2020 in its Q3 2020 Earnings Press Release issued on 21 October 2020.
Condition: Alzheimers
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.